Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases

US6759401B2 · kind B2 · utility

Assignee

• Biovitrum AB · SE

Inventors

• Bjorn Nilsson · Foster City, US
• Jan Tejbrant · Stuvsta-Snättringe, SE
• Benjamin Pelcman · Stockholm, SE
• Erik Ringberg · Uppsala, SE
• Markus Thor · Knivsta, SE
• Jonas Nilsson · Lindome, SE
• Mattias Jonsson · Uppsala, SE

Key dates

• Filing date: Oct 11, 2002
• Grant date: Jul 6, 2004
• Expiry date: Oct 11, 2022

Classification

• Technology area (CPC —): General

Abstract

The invention relates to compounds of the general formula (I): whereinAr is optionally substituted aryl or heteroaryl;A is (i) —O—, —S—, —SO2—, —NH—, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members;B is —C(R4)(R5)—, —OC(R4)(R5)—, —N(R6)C(R4)(R5)—, —N(R6)—, —O—, —S— or —SO2—;R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl;R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R4)(R5)]xN(R2a)(R3a)];R2a, R3a, R4, R5, R6 and x are as defined in the claims, and n is 0 or 1; and pharma…